Verona Pharma plc
VRNA
$63.32
-$2.94-4.44%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 113.52M | 42.26M | 5.62M | -- | -- |
| Total Other Revenue | 5.02M | 18.00K | -- | -- | -- |
| Total Revenue | 118.54M | 42.28M | 5.62M | -- | -- |
| Cost of Revenue | 5.99M | 2.58M | 543.00K | -- | -- |
| Gross Profit | 112.55M | 39.70M | 5.08M | -- | -- |
| SG&A Expenses | 198.43M | 149.75M | 119.64M | 97.79M | 61.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 253.27M | 193.31M | 156.93M | 128.87M | 73.19M |
| Operating Income | -134.73M | -151.03M | -151.30M | -128.87M | -73.19M |
| Income Before Tax | -154.65M | -163.13M | -151.76M | -123.69M | -62.37M |
| Income Tax Expenses | 9.30M | 10.29M | 1.97M | 1.76M | 1.06M |
| Earnings from Continuing Operations | -163.94 | -173.42 | -153.72 | -125.45 | -63.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -163.94M | -173.42M | -153.72M | -125.45M | -63.42M |
| EBIT | -134.73M | -151.03M | -151.30M | -128.87M | -73.19M |
| EBITDA | -133.64M | -149.97M | -150.30M | -127.97M | -72.41M |
| EPS Basic | -16.01 | -17.03 | -15.18 | -12.43 | -6.33 |
| Normalized Basic EPS | -1.15 | -1.22 | -1.14 | -0.93 | -0.49 |
| EPS Diluted | -16.27 | -17.29 | -15.45 | -12.70 | -6.60 |
| Normalized Diluted EPS | -1.15 | -1.22 | -1.14 | -0.93 | -0.49 |
| Average Basic Shares Outstanding | 330.35M | 326.14M | 323.50M | 321.79M | 320.07M |
| Average Diluted Shares Outstanding | 41.29M | 40.77M | 40.44M | 40.22M | 40.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |